Mineralys Therapeutics Q1 EPS $(0.47), Inline
Benzinga Newsdesk 5 months ago
EarningsNews
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 40.51 percent increase over losses of $(0.79) per share from the same period last
Mineralys Therapeutics (NASDAQ:MLYS) reported quarterly losses of $(0.47) per share which met the analyst consensus estimate. This is a 40.51 percent increase over losses of $(0.79) per share from the same period last year.